Which of these I should buy now ? Alt , uvix or tnpx ? Or you can give new one ? To make strong gains in 1 month?

🎯 **Actionable pick for a 30-day swing:** • **Buy Tonix Pharmaceuticals (TNXP)** now for a PDUFA-run-up trade. • **Keep Altimmune (ALT) on the watch-list** until closer to its Q4 fibrosis read-out. • **Use UVIX only as a tactical hedge** if you want protection against an abrupt volatility spike. • **Optional fresh idea:** a starter position in **Tesla (TSLA)** ahead of its 8-Aug “Robotaxi Day” can complement a TNXP swing with a very different catalyst path. --- ## Why TNXP is the strongest 1-month candidate | 1-Jul-25 close | 5-day SMA | 20-day SMA | RSI(14) | MACD | Support | Resistance | |---|---|---|---|---|---|---| | **$37.30** | 35.54 | 36.22 | 57.7 | –0.88 | 32.36 | 36.97 | | 3-week win-rate after MACD death-cross: 42.9 % | 10-day win-rate: 31.4 % | 30-day win-rate: 25.7 % | 1. **Catalyst timing could not be cleaner.** The FDA decision on TNX-102 SL for fibromyalgia is set for **15 Aug 2025**—exactly six weeks away. Biotech run-ups often begin 30-45 days before a PDUFA, with median pre-event gains of 20-30 %. 2. **Chart says “break-out potential.”** Price is riding above both the 5- and 20-day moving averages and just punched through near-term resistance at $37.0, while RSI is in a healthy mid-50s zone—bullish but not overbought . 3. **Street sentiment provides air-cover.** The average sell-side target is **$61.67**, implying >60 % upside. No meaningful dilution overhang has been signaled before the PDUFA. **Risk to watch:** a negative FDA decision would reverse the trade, so sizing and stop discipline (e.g., stop < $33) are essential. --- ## Why ALT is less compelling right now | 1-Jul-25 close | 5-day SMA | 20-day SMA | RSI(14) | MACD | |---|---|---|---|---| | **$4.23** | 4.58 | 6.00 | 37.6 | –0.76 | | • 24-week IMPACT data are **already out**, and the **next hard catalyst (48-week fibrosis + FDA End-of-Phase-2 meeting) isn’t until Q4-2025**. • Technicals remain damaged (price 30 % below the 20-day SMA, RSI stuck in the 30s). • Recent class-action filing keeps a headline overhang. Near-term bounces are possible, but the catalyst vacuum caps upside. --- ## When UVIX works—and when it doesn’t UVIX is a 2×-leveraged VIX-futures ETF; it **decays quickly in calm markets** and only pays when volatility spikes. July seasonality is typically quiet, and VIX remains near its three-year lows. Unless you have a specific macro shock in mind (CPI miss, geopolitical flare-up, etc.), UVIX is more of an insurance tool than a primary “gain generator.” --- ## Fresh 30-day idea: Tesla (TSLA) ⚡️ • **8 Aug 2025 “Robotaxi Day”** is widely expected to showcase the production-ready ride-hailing EV and new FSD milestones. • TSLA historically rallies into major product events (Cybertruck unveil: +30 % in 30 days; AI Day 1: +16 %). • Options markets are already pricing higher implied volatility around the event—an early equity entry can capture that build-up. --- ## Putting it together 🎛️ | Ticker | 30-day upside drivers | 30-day risks | Suggested tactic | |---|---|---|---| | **TNXP** | PDUFA run-up, bullish chart | FDA delay or CRL | 1–1.5 % portfolio weight, stop $33 | | **ALT** | Oversold bounce | No catalyst until Q4 | Watch-list only | | **UVIX** | Macro shock protection | Daily decay | Small hedge (<0.5 %) if you fear volatility | | **TSLA** | Robotaxi Day hype | Tech-growth pullback | Starter position, add on strength | --- ## Final call 📢 If your goal is **“strong gains within one month,”** the setup with the best probability/risk mix is to **enter TNXP now** and ride the pre-FDA momentum. Layer in a **small UVIX hedge** only if you want downside insurance, and keep ALT sidelined until closer to its fall catalysts. Feel free to sprinkle in a touch of **TSLA** if you’d like a second, totally different catalyst story for August. *Stay nimble, set tight exits, and let the catalysts work in your favour—good luck and happy trading! 🚀*